Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Kate Corrigan, Maeve Haran, Conor Mccandliss, Róisín M. Mcmanus, Shannon Cleary, Rebecca Trant, Yazeed Kelly, Kathryn Ledden, Gavin Rush, Veronica O’keane, John R. Kelly
Irish Journal of Medical Science June 15, 2021 DOI: 10.1007/s11845-021-02668-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 99 |
| Population | Mental health service users |
| Topics | Anxiety Psilocybin Psychedelic-assisted therapy |
| Keywords | Mental health Clinical psychology Hallucinogen Perception |
| Citations | 79 |
| Key findings | The majority of mental health service users supported further research into psilocybin therapy, with younger age, prior psychedelic experience, and non-religious beliefs associated with more favorable attitudes. |
Abstract
Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes.
Objectives: To explore mental health service user attitudes to psychedelics and psilocybin therapy.
Methods: A questionnaire capturing demographics, diagnoses, previous psychedelic and other drug use, and attitudes to psychedelics and psilocybin therapy was distributed to mental health service users.
Results: Ninety-nine participants completed the survey (52% female, mean age 42 years). The majority (72%) supported further research, with 59% supporting psilocybin as a medical treatment. A total of 27% previously used recreational psilocybin, with a male preponderance (p = 0.01). Younger age groups, those with previous psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin. A total of 55% of the total sample would accept as a treatment if doctor recommended, whereas 20% would not. Fewer people with depression/anxiety had used recreational psychedelics (p = 0.03) but were more likely to support government funded studies (p = 0.02). A minority (5%) of people with conditions (psychosis and bipolar disorder) that could be exacerbated by psilocybin thought it would be useful for them. One fifth of the total sample viewed psychedelics as addictive and unsafe even under medical supervision. Concerns included fear of adverse effects, lack of knowledge, insufficient research, illegality, and relapse if medications were discontinued.
Conclusions: The majority supported further research into psilocybin therapy. Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.
Comparable studies
Other cross-sectional and survey studies on psilocybin for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Microdosing psychedelics: Motivations, subjective effects and harm reduction People aged 16 years or older who had used psychedelics and could comprehend written... | 2019 | Cross-sectional survey | n = 525 |
| People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences Black, Indigenous, and people of color (BIPOC) in the US and Canada | 2020 | Cross-sectional survey | n = 313 |
| Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey Adults planning to take psilocybin outside clinical research, primarily... | 2023 | Prospective longitudinal survey | n = 2,833 |
Citations in the library
Cited by 78
- Psychedelics and Other Psychoplastogens for Treating Mental Illness Frontiers in Psychiatry October 4, 2021
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective Frontiers in Psychiatry December 17, 2021
- The economics of psychedelic-assisted therapies: A research agenda Frontiers in Psychiatry December 5, 2022
- The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy Frontiers in Psychiatry November 26, 2021
- Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review Journal of Psychedelic Studies February 5, 2024
and 73 more in the library
Cites 72
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
and 67 more in the library